


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.


Listing of the Claims:

Claim 1 (currently amended): A process for the manufacture of the calcium salt of (*E*)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3*R*,5*S*)-3,5-dihydroxyhept-6-enoic acid, comprising:

a) acid hydrolysis of an acetal protecting group in a compound of the formula (7)




wherein A is an acetal or ketal protecting group and R is (1-6C)alkyl, and isolation of a resulting crystalline compound of the formula (8)



b) optional recrystallisation of the compound of the formula (8);

c) hydrolysis of the ester group in the compound of formula (8) to give a dihydroxy carboxylate derivative of formula (9) (wherein M is hydrogen or a metal counterion other than calcium);




9

or a the calcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-3R,5S-3,5-dihydroxyhept-6-enoic acid compound of the formula (1); and

d) where necessary, conversion of a the compound of the formula (9), where present, into a the calcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-3R,5S-3,5-dihydroxyhept-6-enoic acid compound of the formula (1).

Claim 2 (currently amended): A The process as claimed in Claim 1 wherein the compound of the formula (7) is a compound of the formula (7a).



7a

Claim 3 (original): A process for the manufacture of the calcium salt of *(E)*-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3*R*,5*S*)-3,5-dihydroxyhept-6-enoic acid, from a crystalline compound of formula (8) as claimed in steps c) and d) of Claim 1.

Claim 4 (currently amended): ~~A-The process as claimed in Claim 1 or Claim 2 or Claim 3~~
1 wherein R is methyl, ethyl, iso-propyl, tert-butyl or hexyl.

Claim 5 (currently amended): ~~A-The process as claimed in any one of Claims 1 to 4~~
1 wherein R is ethyl, iso-propyl or tert-butyl.

Claim 6 (currently amended): A crystalline compound of the formula 7-(7) as defined in Claim 1, which crystalline compound is methyl *(E)*-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4*R*,6*S*)-2,2-dimethyl[1,3]dioxan-4-yl)acetate having an X-ray powder diffraction pattern with peaks at 2-theta = 9.5, 13.6 and 17.5.

Claim 7 (currently amended): A crystalline compound of the formula 7-(7) as defined in Claim 1, which crystalline compound is ethyl (E)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}{(4R,6S)-2,2-dimethyl[1,3]dioxan-4-yl)acetate having an X-ray powder diffraction pattern with peaks at 2-theta = 15.9, 18.4 and 19.5.

Claim 8 (currently amended): A crystalline compound of the formula 7-(7) as defined in Claim 1, which crystalline compound is iso-propyl (E)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}{(4R,6S)-2,2-dimethyl[1,3]dioxan-4-yl)acetate having an X-ray powder diffraction pattern with peaks at 2-theta = 7.8, 11.6 and 15.5.

Claim 9 (currently amended): A crystalline compound of the formula 7-(7) as defined in Claim 1, which crystalline compound is n-hexyl (E)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}{(4R,6S)-2,2-dimethyl[1,3]dioxan-4-yl)acetate having an X-ray powder diffraction pattern with peaks at 2-theta = 5.3, 7.1 and 18.9.


Claim 10 (currently amended): A crystalline compound of the formula 8-(8) as defined in Claim 1, which crystalline compound is ethyl-(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoate having an X-ray powder diffraction pattern with peaks at 2-theta = 8.1, 11.3 and 19.9.

Claim 11 (currently amended): A crystalline compound of the formula 8-(8) as defined in Claim 1, which crystalline compound is iso-propyl-(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoate having an X-ray powder diffraction pattern with peaks at 2-theta = 9.8, 17.3 and 21.1.


Claim 12 (cancelled).

Claim 13 (currently amended): A process for the manufacture of the calcium salt of (*E*)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3*R*,5*S*)-3,5-dihydroxyhept-6-enoic acid, comprising:


a) acid hydrolysis of an acetal protecting group in a compound of the formula (7)



wherein A is an acetal or ketal protecting group and R is (1-6C)alkyl, and isolation of the resulting crystalline compound of the formula (10);



b) optional recrystallisation of the compound of the formula (10);
c) hydrolysis of the compound of formula (10) to give a dihydroxy carboxylate derivative of formula (9) (wherein M is a metal counterion other than calcium),




9

or a-the calcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid compound of the formula (1); and

d) where necessary, conversion of a-the compound of the formula (9), where present, into a-the calcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid compound of the formula (1).

Claim 14 (currently amended): A process as claimed in Claim 13 wherein the compound of the formula (7) is a compound of the formula (7a).



7a

Claim 15 (original): A process for the manufacture of the calcium salt of *(E)*-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3*R*,5*S*)-3,5-dihydroxyhept-6-enoic acid, from a crystalline compound of formula (10) as claimed in steps b) and c) of Claim 13.

Claim 16 (original): Crystalline *(E)*-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3*R*,5*S*)-3,5-dihydroxyhept-6-enoic acid-(3,6)-lactone having an X-ray powder diffraction pattern with peaks at 2-theta = 7.9, 11.9, 15.9, 20.3, 21.7 and 22.5.

Claim 17 (original): A process for formation of amorphous bis[*(E)*-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3*R*,5*S*)-3,5-dihydroxyhept-6-enoic acid] calcium salt comprising isolation of a crystalline compound as claimed in Claim 16 from a solution and subsequent conversion to the amorphous form of bis[*(E)*-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3*R*,5*S*)-3,5-dihydroxyhept-6-enoic acid] calcium salt.

Claims 18-20 (cancelled).